PMAM
REGN icon

Picton Mahoney Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Picton Mahoney Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,408
Closed -$11.9M – 1604
2026
Q1 		$11.9M Sell
15,408
-176
-1% -$135K 0.09% 210
2025
Q4 		$12M Buy
15,584
+7,349
+89% +$4.99M 0.09% 185
2025
Q3 		$4.63M Buy
8,235
+8,234
+823,400% +$4.66M 0.04% 296
2025
Q2 		$1K Hold
1
– – ﹤0.01% 904
2025
Q1 		$1K Hold
1
– – ﹤0.01% 867
2024
Q4 		$1K Hold
1
– – ﹤0.01% 784
2024
Q3 		$1K Buy
+1
New +$1.11K ﹤0.01% 768
2020
Q3 		– Sell
-6,490
Closed -$4.05M – 388
2020
Q2 		$4.05M Sell
6,490
-2,635
-29% -$1.5M 0.23% 117
2020
Q1 		$4.46M Buy
+9,125
New +$3.76M 0.25% 94

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Picton Mahoney Asset Management's REGN Position: Q2 2026 in Review

Picton Mahoney Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 15,408 shares — an estimated $11.9M sold.

Picton Mahoney Asset Management first reported a position in REGN in Q1 2020 and held it in 9 quarters. The position peaked at $12M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Picton Mahoney Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 15,408 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $11.9M.
  • Picton Mahoney Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Picton Mahoney Asset Management's Regeneron Pharmaceuticals position peaked at $12M in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.